Author

Patricia Martin‐Regueira

Observed names: P Martin-Regueira, P Martín-Regueira, P. Martin-Regueira, P. Martin‐Regueira, P. Martín Regueira, P. Martín‐Regueira, Patricia Martin Regueira, Patricia Martin-Regueira, Patricia Martín-Regueira

Institution: Bristol-Myers Squibb (Switzerland)

Observed institutions: Bristol-Myers Squibb (United States), Hospital Universitario de La Princesa, Bristol-Myers Squibb (Switzerland), University of Turin

OpenAlex ID: A5034612965

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial

2021 · Courtney D DiNardo, Andre C Schuh, et al. · The Lancet Oncology · 197

Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study

2019 · Neil P. Shah, Valentín García-Gutiérrez, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 148

Enasidenib vs conventional care in older patients with late-stage mutant- IDH2 relapsed/refractory AML: a randomized phase 3 trial

2022 · Stéphane de Botton, Pau Montesinos, et al. · Blood · 121

PDF

Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma

2020 · Philippe Armand, Ann Janssens, et al. · Blood · 95

PDF

Hematopoietic cell transplantation in acute lymphoblastic leukemia: better long term event-free survival with conditioning regimens containing total body irradiation.

2000 · E Granados, R de La Cámara, et al. · PubMed · 64

Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study

2020 · Jorge E. Cortes, Qian Jiang, et al. · Leukemia · 56

PDF

Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial

2023 · Stephen P Hunger, Thai Hoa Tran, et al. · The Lancet Haematology · 41

High incidence of autoimmune alterations in chronic myeloid leukemia patients treated with interferon‐α

2003 · J.L. Steegmann, M.J. Requena, et al. · American Journal of Hematology · 37

PDF

Treatment‐free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5‐year analysis of DASFREE

2023 · Neil P. Shah, Valentín García‐Gutiérrez, et al. · British Journal of Haematology · 28

PDF

Treatment-Free Remission (TFR) in Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP) and in Stable Deep Molecular Response (DMR) to Dasatinib - the Dasfree Study

2016 · Neil P. Shah, Ronald Paquette, et al. · Blood · 27

The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study

2021 · Joaquín Martínez-López, Satu Mustjoki, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 14

Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial

2022 · Vikas Gupta, Abdulraheem Yacoub, et al. · Blood · 13

Outcomes for Patients with Late-Stage Mutant-IDH2 (m IDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial

2021 · Courtney D. DiNardo, Pau Montesinos, et al. · Blood · 10

Updated 18-Month Results from Dasfree: A Study Evaluating Dasatinib Discontinuation in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR)

2018 · Neil P. Shah, Jose Valentín García Gutiérrez, et al. · Blood · 9

Phase 1/2 Study Investigating CC-90011, a Potent, Selective, and Reversible Oral Inhibitor of Lysine-Specific Demethylase 1 (LSD1), Plus Concurrent Venetoclax (VEN) and Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML)

2021 · Courtney D. DiNardo, Gautam Borthakur, et al. · Blood · 6

Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern

2018 · Jorge E. Cortes, Qian Jiang, et al. · Blood · 5

Achieving clinically meaningful changes in haemoglobin levels in patients with non‐transfusion‐dependent β‐thalassaemia treated with luspatercept: A post hoc analysis of the phase 2 BEYOND trial

2025 · Khaled M. Musallam, Ali T. Taher, et al. · British Journal of Haematology · 4

Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to 3 months of imatinib therapy: final 5-year results from DASCERN

2024 · Jorge E. Cortes, Qian Jiang, et al. · Haematologica · 4

PDF

Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial.

2022 · Stéphane De Botton, Alberto Risueño, et al. · Journal of Clinical Oncology · 4

2022 · Courtney Denton Dinardo, Pau Montesinos, et al. · Journal of Clinical Oncology · 4

Safety data from the non-transfusion-dependent dose-confirmation cohort: A phase 2a study of luspatercept in pediatric patients with β-thalassemia

2025 · Vip Viprakasit, Jianpei Fang, et al. · Blood · 2

PDF

DASFREE: Treatment-Free Remission (TFR) After Discontinuation of Dasatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR)

2019 · Neil P. Shah, J. Valentín García-Gutiérrez, et al. · Clinical Lymphoma Myeloma & Leukemia · 2

Pf408 Dasfree 2‐year Update: Dasatinib Discontinuation in Patients (pts) With Chronic Myeloid Leukemia in Chronic Phase (cml‐cp) and Deep Molecular Response (dmr)

2019 · N. Shah, J.V. García‐Gutiérrez, et al. · HemaSphere · 2

Fedratinib Induces Cytokine Changes Correlating with Clinical Response in Ruxolitinib Exposed Myelofibrosis Patients: Biomarker Analysis from the Freedom Trial

2022 · Danny V Jeyaraju, Sheida Hayati, et al. · Blood · 1

P700: Treatment-free Remission (tfr) After Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (cml-cp) and Deep Molecular Response (dmr): Final 5-year Results of Dasfree

2022 · N. P. Shah, V. García-Gutiérrez, et al. · HemaSphere · 1

Works count: 37

Citation count: 898

H-index: 12

I10-index: 13